Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Enzalutamide in mCNPC
NCT06015321Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Samsung Medical Center. Primary endpoint: Time to Castration-Resistant Prostate Cancer at 30 months. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06015321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015321.